SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

JP Morgan Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $23

JP Morgan maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $20 to $23.

Benzinga · -

JP Morgan maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $20 to $23.